OBJECTIVE: To determine whether measurement of telomere DNA content (TC) in prostate biopsy tissue predicts prostate-specific antigen (PSA) recurrence in men after undergoing radical prostatectomy for prostate cancer. METHODS: Slot blot titration assay was used to quantitate TC in archived diagnostic prostate needle biopsy specimens for subjects (n = 103) diagnosed with prostate cancer and who subsequently underwent radical prostatectomy between 1993 and 1997. TC was compared to the clinical outcome measure; PSA recurrence, defined as an increase in PSA > or = 0.2 ng/mL on 2 or more consecutive measurements post-prostatectomy, was observed retrospectively, for a mean follow-up period of 114 months (range, 1-165). RESULTS: In the cohort, 46 subjects had a PSA recurrence. In a univariate Cox proportional hazards model, low TC (< 0.3 of standard) demonstrated a significant risk for PSA recurrence (HR = 1.94; 95% CI: 1.02-3.69, P = .04). In a subset analysis of men with biopsy Gleason sum < or = 6 (n = 63; 25 recurrences), a univariate Cox proportional hazards model demonstrated that low TC had a greater risk of PSA recurrence (HR = 4.53; 95% CI: 2.00-10.2, P < .01). In a multivariate Cox proportional hazards model, low TC was also significantly associated with PSA recurrence in this subset after controlling for preoperative PSA levels (HR = 6.62; 95% CI: 2.69-16.3, P < .01). CONCLUSIONS: Low TC measured in prostate biopsy tissue predicts early likelihood of post-prostatectomy PSA recurrence in a retrospective analysis, and in men with biopsy Gleason sum < or = 6 disease it is also independent of preoperative PSA level. 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: To determine whether measurement of telomere DNA content (TC) in prostate biopsy tissue predicts prostate-specific antigen (PSA) recurrence in men after undergoing radical prostatectomy for prostate cancer. METHODS: Slot blot titration assay was used to quantitate TC in archived diagnostic prostate needle biopsy specimens for subjects (n = 103) diagnosed with prostate cancer and who subsequently underwent radical prostatectomy between 1993 and 1997. TC was compared to the clinical outcome measure; PSA recurrence, defined as an increase in PSA > or = 0.2 ng/mL on 2 or more consecutive measurements post-prostatectomy, was observed retrospectively, for a mean follow-up period of 114 months (range, 1-165). RESULTS: In the cohort, 46 subjects had a PSA recurrence. In a univariate Cox proportional hazards model, low TC (< 0.3 of standard) demonstrated a significant risk for PSA recurrence (HR = 1.94; 95% CI: 1.02-3.69, P = .04). In a subset analysis of men with biopsy Gleason sum < or = 6 (n = 63; 25 recurrences), a univariate Cox proportional hazards model demonstrated that low TC had a greater risk of PSA recurrence (HR = 4.53; 95% CI: 2.00-10.2, P < .01). In a multivariate Cox proportional hazards model, low TC was also significantly associated with PSA recurrence in this subset after controlling for preoperative PSA levels (HR = 6.62; 95% CI: 2.69-16.3, P < .01). CONCLUSIONS: Low TC measured in prostate biopsy tissue predicts early likelihood of post-prostatectomy PSA recurrence in a retrospective analysis, and in men with biopsy Gleason sum < or = 6 disease it is also independent of preoperative PSA level. 2010 Elsevier Inc. All rights reserved.
Authors: Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Colleen A Fordyce; Christopher M Heaphy; Nancy E Joste; Anthony Y Smith; William C Hunt; Jeffrey K Griffith Journal: J Urol Date: 2005-02 Impact factor: 7.450
Authors: N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay Journal: Science Date: 1994-12-23 Impact factor: 47.728
Authors: C Gu; Q Li; Y Zhu; Y Qu; G Zhang; M Wang; Y Yang; J Wang; L Jin; Q Wei; D Ye Journal: Prostate Cancer Prostatic Dis Date: 2015-08-04 Impact factor: 5.554
Authors: Christopher M Heaphy; Trisha M Fleet; Eric G Treat; Sang-Joon Lee; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi Journal: Prostate Date: 2010-09-15 Impact factor: 4.104
Authors: Christopher M Heaphy; Gaurav Gaonkar; Sarah B Peskoe; Corinne E Joshu; Angelo M De Marzo; M Scott Lucia; Phyllis J Goodman; Scott M Lippman; Ian M Thompson; Elizabeth A Platz; Alan K Meeker Journal: Prostate Date: 2015-04-20 Impact factor: 4.104
Authors: Anna C Jones; Kristina A Trujillo; Genevieve K Phillips; Trisha M Fleet; Jaclyn K Murton; Virginia Severns; Satyan K Shah; Michael S Davis; Anthony Y Smith; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi Journal: Prostate Date: 2011-11-29 Impact factor: 4.104
Authors: Benjamin A Rybicki; Sudha M Sadasivan; Yalei Chen; Ian Loveless; Nilesh S Gupta; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang L Tang Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Christopher M Heaphy; Ghil Suk Yoon; Sarah B Peskoe; Corinne E Joshu; Thomas K Lee; Edward Giovannucci; Lorelei A Mucci; Stacey A Kenfield; Meir J Stampfer; Jessica L Hicks; Angelo M De Marzo; Elizabeth A Platz; Alan K Meeker Journal: Cancer Discov Date: 2013-06-18 Impact factor: 39.397
Authors: Anna C Jones; Kresta S Antillon; Shannon M Jenkins; Sara N Janos; Heidi N Overton; Dor S Shoshan; Edgar G Fischer; Kristina A Trujillo; Marco Bisoffi Journal: PLoS One Date: 2015-03-13 Impact factor: 3.240